|
1
|
Cools J, Maertens C and Marynen P:
Resistance to tyrosine kinase inhibitors: Calling on extra forces.
Drug Resist Updat. 8:119–129. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sato H, Oka T, Shinnou Y, Kondo T, Washio
K, Takano M, Takata K, Morito T, Huang X, Tamura M, et al:
Multi-step aberrant CpG island hyper-methylation is associated with
the progression of adult T-cell Leukemia/lymphoma. Am J Pathol.
176:402–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheng X and Blumenthal RM: Mammalian DNA
methyltransferases: A structural perspective. Structure.
16:341–350. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y,
Zhang Z, He Q and Chang C: Overexpression of the EZH2, RINGl and
BMIl genes is common in myelodysplastic syndromes: Relation to
adverse epigenetic alteration and poor prognostic scoring. Ann
Hematol. 90:643–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nagel S, Venturini L, Marquez VE, Meyer C,
Kaufmann M, Scherr M, MacLeod RA and Drexler HG: Polycomb repressor
complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell
lines. Mol Cancer. 9:1512010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu X, Gong Y, Yue J, Qiang B, Yuan J and
Peng X: Cooperation between EZH2, NSPc1-mediated histone H2A
ubiquitination and Dnmt1 in HOX gene silencing. Nucleic Acids Res.
36:3590–3599. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kanduri M, Sander B, Ntoufa S,
Papakonstantinou N, Sutton LA, Stamatopoulos K, Kanduri C and
Rosenquist R: A key role for EZH2 in epigenetic silencing of HOX
genes in mantle cell lymphoma. Epigenetics. 8:1280–1288. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qi J, Zhu YQ, Luo J, Tao WH and Zhang JM:
Hypermethylation and regulation of expression of secreted
frizzled-related protein genes in colorectal tumor. Zhonghua Zhong
Liu Za Zhi. 29:842–845. 2007.(In Chinese). PubMed/NCBI
|
|
10
|
Reddy J, Shivapurkar N, Takahashi T,
Parikh G, Stastny V, Echebiri C, Crumrine K, Zöchbauer-Müller S,
Drach J, Zheng Y, et al: Differential methylation of genes that
regulate cytokine signaling in lymphoid and hematopoietic tumors.
Oncogene. 24:732–736. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Migone TS, Cacalano NA, Taylor N, Yi T,
Waldmann TA and Johnston JA: Recruitment of SH2 containing protein
tyrosinephosphatase SHP-1 to the interleukin 2 receptor; loss of
SHP-1 expression in human T-lymphotropic virus type I transformedT
cells. Proc Natl Acad Sci USA. 95:pp. 3845–3850. 1998; View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Uhm KO, Lee ES, Lee YM, Park JS, Kim SJ,
Kim BS, Kim HS and Park SH: Differential methylation pattern of
ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic
myeloid leukemia. J Korean Med Sci. 24:493–497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chase A and Cross NC: Aberrations of EZH2
in cancer. Clin Cancer Res. 17:2613–2618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He IJ, Cai MY, Xu GL, Li JJ, Weng ZJ, Xu
DZ, Luo GY, Zhu SL and Xie D: Prognostic significance of
overexpression of EZH2 and H3k27me3 proteins in gastric cancer.
Asian Pac J Cancer Prev. 13:3173–3178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McCabe MT, Ott HM, Ganji G, Korenchuk S,
Thompson C, van Aller GS, Liu Y, Graves AP, Pietra A Della III,
Diaz E, et al: EZH2 inhibition as a therapeutic strategy for
lymphoma with EZH2-activating mutations. Nature. 492:108–112. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fiskus W, Wang Y, Sreekumar A, Buckley KM,
Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, et al:
Combined epigenetic therapy with the histone methyltransferase EZH2
inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor
panobinostat against human AML cells. Blood. 114:2733–2743. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Simon JA and Lange CA: Roles of the EZH2
histone methyltransferase in cancer epigenetics. Mutat Res.
647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao R, Tsukada Y and Zhang Y: Role of
Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol
Cell. 20:845–854. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wilson BG, Wang X, Shen X, McKenna ES,
Lemieux ME, Cho YJ, Koellhoffer EC, Pomeroy SL, Orkin SH and
Roberts CW: Epigenetic antagonism between polycomb and SWI/SNF
complexes during oncogenic transformation. Cancer Cell. 18:316–328.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bracken AP, Dietrich N, Pasini D, Hansen
KH and Helin K: Genome-wide mapping of polycomb target genes
unravels their roles in cell fate transitions. Genes Dev.
20:1123–1136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuser-Abali G, Alptekin A and Cinar B:
Overexpression of MYC and EZH2 cooperates to epigenetically silence
MST1 expression. Epigenetics. 9:634–643. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vire E, Brenner C, Deplus R, Blanchon L,
Fraga M, Didelot C, Morey L, van Eynde A, Bernard D, Vanderwinden
JM, et al: The polycomb group protein EZH2 directly controls DNA
methylation. Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nishioka C, Ikezoe T, Yang J, Udaka K and
Yokoyama A: Imatinib causes epigenetic alterations of PTEN gene via
upregulation of DNA methyltransferases and polycomb group proteins.
Blood Cancer J. 1:e482011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen JH: Epigenetic studies of mesenchymal
and B-cell leukemia. Beijing: Chinese Academy of Medical Sciences,
Peking Union Medical College; 2010
|
|
25
|
Sharma A, Heuck CJ, Fazzari MJ, Mehta J,
Singhal S, Greally JM and Verma A: DNA methylation alterations in
multiple myeloma as a model for epigenetic changes in cancer. Wiley
Interdiscip Rev Syst Biol Med. 2:654–669. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Witzig TE, Hu G, Offer SM, Wellik LE, Han
JJ, Stenson MJ, Dogan A, Diasio RB and Gupta M: Epigenetic
mechanisms of protein tyrosine phosphatase 6 suppression in diffuse
large B-cell lymphoma: Implications for epigenetic therapy.
Leukemia. 28:147–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen X, Fu R, Wang Y, Song W, Ruan E, Qu
W, Wang H, Wang G, Song J, Wang X, et al: Plasma DNA methylation of
shp1 in patients with diffuse large B cell lymphoma. Zhonghua Yi
Xue Za Zhi. 94:1071–1075. 2014.(In Chinese). PubMed/NCBI
|
